Close menu




December 8th, 2022 | 09:05 CET

Where the money is made: BioNTech, Novavax, Cardiol Therapeutics

  • Biotechnology
  • Covid19
  • CBD
Photo credits: pixabay.com

While the first federal states in Germany are lifting the mask requirement on public transport, suppliers of vaccines and medicines are far from going back to normal. Even corona vaccines are in high demand. While there is a shortage of antipyretics and medication in this country, especially for children, innovative companies are already addressing the next challenges. We explain where investors can make money.

time to read: 2 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , CARDIOL THERAPEUTICS | CA14161Y2006 , NOVAVAX INC. DL-_01 | US6700024010

Table of contents:


    BioNTech: Good starting position

    Recently, the BioNTech share price experienced a minor shock: In the legal dispute with Moderna, the Mainz-based company filed a counterclaim with its partner Pfizer. The share price then dipped briefly - investors do not like legal disputes. However, the decline did not cloud the overall chart picture. BioNTech's share price is still driven by the Corona vaccine. Above all, the hope of orders from China makes investors' hearts beat faster. But BioNTech is also doing well in other regions of the world: most recently, Bahrain also opted for the adapted vaccine. Current studies show that the adapted vaccines are worthwhile. According to these, the antibody level in people over 55 years of age increases ninefold with the BQ1.1 variant.

    Novavax: The air is out

    Since BioNTech is flexibly positioned thanks to its mRNA technology and can also focus on other diseases, such as cancer, the stock remains promising. Although the stock is moving sideways between EUR 127 and EUR 176 in 2022, this could be a good starting point for rising prices towards old highs in the long term. The Novavax share also looks attractive from a chart perspective at first glance. However, a closer look reveals differences. First, Novavax does not rely on modern mRNA technology. In the race with the top dogs BioNTech and Moderna, Novavax cannot keep up with its delayed market entry. Only the vaccine against the RS virus, which is currently circulating strongly among children, gave hope for a while - but it ultimately failed in Phase 3 of the clinical trials. While the BioNTech share could regain its strength in the long term, Novavax is likely to have run out of steam for the time being.

    Cardiol Therapeutics: Enormous comeback potential

    At first glance, the air is also out of the Cardiol Therapeutics share. Within the past 14 months, the stock has plummeted from around USD 4.60 to the current level of USD 0.52. What happened? The innovative biotech company, which focuses on inflammatory diseases of the heart, raised fresh capital in 2021 to advance its clinical trials. Fortunately, it could do so at much higher prices than today. The general market environment and share dilution subsequently led to a sell-off at Cardiol. Finally, a few weeks ago, a research program to investigate the effect of the active ingredient CardiolRx in COVID patients was cancelled. Although the drug is still expected to be effective when COVID patients develop concomitant diseases such as myocarditis, the Company simply could not find enough patients to complete the study. Cardiol is now focusing on myocarditis, pericarditis and acute heart failure. Around the first two conditions, Cardiol Therapeutics is in Phase 2 of the development pipeline.


    When pharmacologists are asked about the prospects for Cardiol Therapeutics, they praise the study design in particular. It is capable of producing clear results and also relies on modern methods. While the Novavax share has little chance of surprising positively with its current pipeline, the situation with Cardiol Therapeutics is different. The Company has the necessary capital and has launched promising studies. The active ingredient CBD is considered extremely low in side effects and has already demonstrated anti-inflammatory effects in many studies. Given the sell-off of the Cardiol Therapeutics share, investors should note the value - a dynamic catch-up movement cannot be ruled out here. It is worth keeping an eye on the newsflow! As soon as something happens here, the Nasdaq-listed stock should quickly be back in the focus of investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a "Transaction"). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company.
    In this respect, there is a concrete conflict of interest in the reporting on the companies.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
    For this reason, there is also a concrete conflict of interest.
    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author



    Related comments:

    Commented by Juliane Zielonka on June 1st, 2023 | 09:30 CEST

    BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

    • Biotechnology
    • Pharma
    • AI

    Tech investors have suffered heavy losses over the past year. But tech in pharma and security in defence enables entirely new future scenarios whose precise developments are worth examining more closely. For example, gentler and more effective new ways that benefit patients are emerging in the drug delivery market. At the forefront is the Company BioNxt Solutions, which specializes in innovative transdermal patches whose active ingredients literally go under the skin. In Germany, the biotech company cooperates with a German pharmaceutical partner. New times are now dawning for Bayer as well. Under the new reign of CEO Bill Anderson, digital health seems to have finally found its positioning in the Consumer Health division. There, the Company is to cooperate with exciting start-ups that collect and analyze consumer data. When it comes to networking and interpreting data using AI, one company in particular stands out at the moment. Palantir is moving out to "dominate the entire market." How? Find out in the comments below.

    Read

    Commented by Fabian Lorenz on June 1st, 2023 | 08:45 CEST

    JinkoSolar, BioNTech and First Phosphate with important updates: This is what moves the shares

    • Mining
    • phosphate
    • photovoltaics
    • Biotechnology

    The energy transition is moving forward. In Germany, the traffic light government seems to have agreed on a new heating law. In the US, the agreement between Democrats and Republicans on the debt ceiling is a good sign for the industry because the promotion of environmentally friendly technologies depends on it. JinkoSolar and First Phosphate, among others, should benefit from this. Both companies have published important updates. There is also important news at BioNTech. However, these are not so positive. When will there be new impulses for the share?

    Read

    Commented by André Will-Laudien on May 31st, 2023 | 08:30 CEST

    Biotech in turnaround mode! BioNTech, Defence Therapeutics, MorphoSys, Formycon - Take a close look at these shares!

    • Biotechnology
    • Pharma
    • vaccine

    Since the major pandemic wave in the biotech sector, most industry players have had to come to terms with normality again. Scolded investors quickly learned their lesson and are now looking warily at an industry that experienced its heyday between 2019 and 2021. Today, it is no longer the small announcements of hope that lead to significant price swings. After months of sell-offs, however, the sector is stabilizing for the first time, and some protagonists can report minor progress. When the sector trend weakens, selection is the trump card. Here are some suggestions.

    Read